← Back to headlines
Gilead Acquires CAR-T Specialist Arcellx for $7.8 Billion
Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.
23 Feb, 16:44 — 23 Feb, 16:44
Sources
Showing 1 of 1 sources
